Table 2 Main care within the year before index date for the three populations
CAD-T2DM without MI/stroke population | THEMIS-like population | PCI THEMIS-like population | |
|---|---|---|---|
n = 258,260 | n = 64,334 | n = 11,622 | |
General practitioner visit number, mean (± SD) | 10.2 (7.1) | 9.5 (6.8) | 9.5 (6.6) |
Cardiologist visit number, mean (± SD) | 2.3 (2.8) | 2.0 (2.3) | 2.1 (2.4) |
Other specialist visit number, mean (± SD) | 5.3 (7.4) | 4.7 (6.0) | 4.6 (6.0) |
At least one | |||
HbA1c test, n (%) | 22,1237 (85.7) | 52,830 (82.1) | 9666 (83.2) |
Hospitalization, n (%) | 141,149 (54.7) | 30,215 (47.0) | 4963 (42.7) |
PCI, n (%) | 24,413 (9.5) | 1429 (2.2) | 1328 (11.4) |
Antidiabetic drug, n (%) | 227,959 (88.3) | 54,769 (85.1) | 10,037 (86.4) |
CV drug, n (%) | 244,660 (94.7) | 58,550 (91.0) | 10,697 (92.0) |
ASA, n (%) | 164,045 (63.5) | 45,829 (71.2) | 8566 (73.7) |
P2Y12i antiplatelet agent, n (%) | 102,843 (39.8) | 7372 (11.5) | 1703 (14.7) |
Anticoagulant treatment, n (%) | 62,371 (24.2) | 6273 (9.8) | 1182 (10.2) |
Other CV drugs, n (%) | 2429,64 (94.1) | 58,034 (90.2) | 10,598 (91.2) |
Statins | 200,790 (77.7) | 45,935 (71.4) | 8445 (72.7) |
ACEI or ARB | 199,125 (77.1) | 46,335 (72.0) | 8467 (72.9) |
Beta blockers | 172,165 (66.7) | 38,290 (59.5) | 7157 (61.6) |
Diuretics | 108,141 (41.9) | 22,106 (34.4) | 4087 (35.2) |
Calcium channel blockers | 94,237 (36.5) | 21,280 (33.1) | 3907 (33.6) |
Organic nitrates | 55,079 (21.3) | 10,552 (16.4) | 2043 (17.6) |
Other lipid modifying agents than statins | 34,418 (13.3) | 7900 (12.3) | 1484 (12.8) |
Other vasodilators used in cardiac diseases | 27,003 (10.5) | 5431 (8.4) | 1029 (8.9) |